Novartis C.E.O. Defends Company’s Decision to Withhold False Data From the F.D.A.

Responding to the agency’s stern rebuke, Vas Narasimhan, the company’s executive, tried to reassure investors that Novartis did not intentionally deceive the F.D.A. while seeking approval for its $2.1 million gene therapy. KATIE THOMAS https://ift.tt/2YPZ7N5 https://ift.tt/2MMs4qw The New York Times Health Falsification of Data, Drugs (Pharmaceuticals), Genetic Engineering August 7, 2019 at 02:00AM